Virus Filtration
Robust, Efficient, and Reliable Performance
Virosart® virus filter provide industry leading solutions in the virus clearance space offering protection and efficiency in biopharmaceutical manufacturing. Virosart® caters to diverse processing needs, ensuring consistent and effective virus filtration.
Discover more about the various virus filters and their specific uses below, or consult our experts to assist you in selecting the right virus filter for your needs.
Virosart® virus filters are designed to achieve high virus removal performance even under challenging process conditions. They demonstrate robust and reliable retention capabilities, achieving a log reduction value (LRV) of ≥ 4 log10 for small, non-enveloped viruses and ≥ 6 log10 for large, enveloped viruses. This level of performance supports compliance with stringent regulatory requirements and helps ensure final product quality.
Virosart® is engineered with an asymmetric membrane structure that provides an effective barrier to viruses. It supports high flow rates, helping to reduce processing time and improve overall efficiency and reliability in biomanufacturing operations.
The Virosart® family offers a diverse array of products with tailor-made membranes that ensure effective virus removal in downstream processing while also offering risk mitigation in upstream operations.
Virosart® is available in multiple device formats to meet diverse processing requirements and production scales—from scale-down studies to large-scale industrial manufacturing. With options including capsules and cartridges, the product delivers versatility, making it a flexible solution for various manufacturing configurations.
Virus Filtration Portfolio
Find the Right Virus Filter for Your Needs
| Virosart® HF | Virosart® HC | Virosart® CPV | Virosart® Max | Virosart® Media | |
Downstream | Upstream | ||||
| Applications | mAbs and recombinant proteins | Blood and plasma derivatives | hydrophobic feeds | mAbs and recombinant proteins | Virus pre-filtration | Cell culture media and reagents |
| Nominal Filtration Area | 1.7 cm² - 2.4 m² Maxicaps® MR: 4.8 m² - 14.4 m² | 5 cm² - 2.7 m² | 5 cm² - 2.1 m² | 5 cm² - 2.1 m² Maxicaps® MR: 4.2 m² - 18.9 m² | 5 cm² - 1.0 m² Maxicaps® MR: 3 m² - 6 m² |
| Membrane Material | Polyethersulfone | Polyethersulfone | Polyethersulfone | Polyamide | Polyethersulfone |
| View Products | View Products | View Products | View Products | View Products | |
| Learn More | Learn More | ||||
Select Your Product
Supporting Products & Services
Learn More About Virus Filtration
Highlight Asset
Training Videos
Downloads
- Application Guide - Virosart® HF: High Speed Virus Filtration for mAbs and Recombinant Proteins PDF | 3.0 MB
- Filterability Performance PDF | 1.3 MB
- Retention Characteristics PDF | 799.0 KB
- Impact on Cell Growth PDF | 1.1 MB
- Effect of Pressure Release on Virus Retention - Virosart® HF PDF | 863.5 KB
- Effect of Pressure Release on Virus Retention - Virosart® CPV PDF | 1.1 MB
- Effect of Flux Decay on Virus Retention - Virosart® CPV PDF | 617.2 KB
- Mitigate Virus Contamination Risks for Advanced Therapies PDF | 425.5 KB
- Hybrid Solutions for the Implementation and Operation of Fully Single-Use Virus Filters in Stainless Steel Manufacturing Facilities PDF | 417.7 KB
- Virus Filtration Under Challenging Conditions PDF | 379.6 KB
- Robustness Study for Virus-Retentive Filtration of Plasma Derivatives PDF | 409.9 KB
- Fully Single-Use Virus Filtration in Manufacturing – New Concepts and Strategies PDF | 1.3 MB
- Virus Filters Enabling Reliable Process Development in Antibody Processes PDF | 314.5 KB
- Increasing Virus Filter Throughput by Process Optimization Studies PDF | 873.1 KB
- Robustness Study for Virus Filtration of mAb Processes PDF | 878.9 KB
- Concept of a Fully Single-Use Virus Filtration PDF | 973.2 KB
- Adsorptive Pre-filtration to Increase Virus Filter Performance in Blood-Derived Processes PDF | 2.1 MB
- Continous Processing: Challenges and Opportunities of Virus Filtration PDF | 285.8 KB
- Virus Risk Mitigation in Cell Culture Media PDF | 527.9 KB
Publications - Links
Webinars
Frequently Asked Questions
Virus clearance is the process of eliminating or inactivating viruses from biopharmaceutical products to ensure their integrity and purity.
The ICH Q5A guidelines outline the requirements for assessing viral safety in biotechnology products derived from cell lines. They emphasize the need for validated processes that effectively clear viruses, including filtration, inactivation, and removal methods. These guidelines ensure that biopharmaceutical products meet stringent standards, protecting patients from potential viral contamination.
Virus filters remove and retain viruses during bioprocessing by using specialized membranes with pores typically around 20 nm in size. As the fluid passes through the filter, these small pores trap and hold viruses, preventing them from passing through with the rest of the fluid. This helps ensure the final product is free from viral contamination, maintaining reliability and purity in biopharmaceutical manufacturing.
Virosart® HF enhances virus filtration by offering a compact, single-use design that reduces sanitization costs and footprint. Its advanced membrane technology ensures reliable virus retention, even under challenging conditions. By streamlining the filtration process, Virosart® HF improves efficiency and reduces the need for extensive pre-flushing, making it ideal for monoclonal antibodies and recombinant protein applications. This filter's design optimizes virus removal, ensuring the integrity and purity of the final product.
Sartorius offers various tutorials and training videos for the Virosart® HF Lab Module, Virosart® HF Process Module, and Virosart® HC & Virosart® CPV Minisart® Lab Scale virus removal filters. These can be accessed through Sartorius Learning Center.